Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
SynopsisI

Is daily inhaled steroid use necessary in the treatment of mild persistent asthma?

Matthew B. Stanbrook
CMAJ May 24, 2005 172 (11) 1439; DOI: https://doi.org/10.1503/cmaj.050515
Matthew B. Stanbrook
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading
  • © 2005 CMA Media Inc. or its licensors

Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005;352:1519-28.

Background: For years, daily anti-inflammatory therapy has been recommended for all cases of mild persistent asthma, yet asthma patients commonly fail to adhere to this daily regimen. Whether intermittent use can produce acceptable outcomes in this population is unknown.

Design: This multicentre, randomized, double-blind trial enrolled 225 adults with mild persistent asthma (defined as a forced expiratory volume in the first second [FEV1] at least 70% of the predicted value, plus 1 or more of: as-needed β-agonist use more than twice a week but not daily; nocturnal awakening with asthma more than twice a month but not weekly; and variability in diurnal peak expiratory flow [PEF] of 20%– 30%). Patients received either budesonide, 200 μg inhaled twice daily; zafirlukast (a leukotriene inhibitor), 20 mg orally twice daily; or placebo. All of the patients were told to use a short-acting β-agonist as needed and received a written symptom-based action plan providing explicit instructions to start open-label inhaled budesonide therapy for 10 days or oral prednisone therapy for 5 days if their asthma symptoms worsened beyond specified clinical thresholds. Patients were followed for 1 year. The primary outcome was change in morning PEF. Secondary outcomes included change in FEV1, frequency of asthma exacerbations, degree of asthma control, number of symptom-free days and asthma-related quality of life.

Results: The morning PEF improved by similar amounts in the 3 study groups (budesonide 8.3%, zafirlukast, 7.9% and placebo 7.1%, p = 0.90). Compared with daily zafirlukast therapy or intermittent therapy (placebo group), daily budesonide therapy resulted in 26 additional symptom-free days per year (95% confidence interval 1.8– 48.5, p = 0.03) and was associated with better asthma control, less airway reactivity and greater decreases in inflammatory markers. No significant differences were observed between the groups in FEV1 after bronchodilator use, asthma exacerbations or asthma-related quality of life.

Commentary: The study's objective was not to redefine the best therapy for mild persistent asthma but, rather, to determine whether a treatment strategy imitating typical patient use produced acceptable outcomes. The reluctance of many asthma patients to adhere to inhaled steroid therapy, arising from concerns such as cost, adverse effects and inconvenience, is a reality of practice. However, many other patients would consider the additional symptom-free days and improved asthma control to be important enough benefits to make inhaled steroid therapy worthwhile. Although it is reassuring that intermittent treatment may not have serious consequences (at least in the short term), satisfactory outcomes must not be confused with optimal ones.

Since previous randomized trials have shown substantial benefits with inhaled steroid use in mild persistent asthma,1,2 including a reduction in exacerbations, why did the present study find more modest effects? Most likely patients in this study had less severe asthma than patients had in the previous studies. In fact, the investigators selected their cohort through rigorous screening. Even so, 15% of the enrolled patients were later excluded after being found to have more severe asthma during the run-in period. It thus seems unlikely that sufficiently accurate characterization of asthma severity will be achieved in routine practice, which raises concerns about the generalizability of the study's findings. Also, all of the patients received a written self-management plan, another important difference from previous studies. This probably enhanced the ability of the patients to cope with changes in symptoms and may explain in part why all of the groups had improved outcomes regardless of treatment, which consequently attenuates any effects of the study medications.

Practice implications: For patients with mild persistent asthma who do not wish to take inhaled steroid therapy daily, an as-needed treatment strategy may be acceptable, provided it is accompanied by education and an action plan with clear instructions about how and when to increase medication use. Nevertheless, daily inhaled steroid treatment remains the preferred evidence-based therapy because of its clinical benefits demonstrated in this and prior studies.1,2

Footnotes

  • Competing interests: Matthew Stanbrook received travel assistance to attend a meeting sponsored by AstraZeneca.

References

  1. 1.↵
    Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, et al; START Investigators Group. Early intervention with budesonide in mild persistent asthma: a randomized, double-blind trial. Lancet 2003;361:1071-6.
    OpenUrlCrossRefPubMed
  2. 2.↵
    O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001;164:1392-7.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 172 (11)
CMAJ
Vol. 172, Issue 11
24 May 2005
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Is daily inhaled steroid use necessary in the treatment of mild persistent asthma?
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Is daily inhaled steroid use necessary in the treatment of mild persistent asthma?
Matthew B. Stanbrook
CMAJ May 2005, 172 (11) 1439; DOI: 10.1503/cmaj.050515

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Is daily inhaled steroid use necessary in the treatment of mild persistent asthma?
Matthew B. Stanbrook
CMAJ May 2005, 172 (11) 1439; DOI: 10.1503/cmaj.050515
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Does β-blocker prophylaxis improve survival after major noncardiac surgery?
  • The changing ecology of avian flu
  • Applying the 2005 Canadian Hypertension Education Program recommendations: 4. Managing uncomplicated hypertension
Show more Synopsis

Similar Articles

Collections

  • Topics
    • Asthma
    • Drugs: respiratory system

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire